semaglutide alzheimer phase 3 evoke and evoke+: design of two large‐scale, double‐blind, placebo‐controlled, studies evaluating the neuroprotective effects of in early Alzheimer's disease - Atri - 2022 - Alzheimer's & Dementia CTAD Presentation Lays Insights Into

Alzheimers Dement (2016) 12(6):71932

Complementing its insulinotropic effects, GLP-1 also suppresses the release of glucagon, slows gastric emptying and intestinal motility, and induces feelings of satiety 5

That evidence provides useful context for understanding why these medications have generated significant patient interest but does not transfer directly to compounded versions, which operate under a different regulatory framework

Target 1.6-2.2 grams per kilogram of body weight daily (0.7-1.0 grams per pound), distributed across 3-4 meals with at least 30 grams per meal

Those taking GLP-1 (glucagon-like peptide-1) medications for diabetes and weight loss often experience gastrointestinal symptoms but some lesser-known side effects have also been reported

Heart disease and stroke statistics-2019 update: a report from the american heart association